Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease

Raphael Schiffmann, Melvyn P. Heyes, J. M. Aerts, James M. Dambrosia, Marc C. Patterson, Thomas DeGraba, Colette C. Parker, Gregory C. Zirzow, Katherine Oliver, Gioacchino Tedeschi, Roscoe O. Brady, Norman W. Barton, Chandra Nagineni, Christine R. Kaneski, Gary J. Murray, Joseph J. Higgins, Anne Tournay, Tapas K. Banerjee, Constance Kreps, Leland J C ScottMary Ann McKee, Kevin Crutchfield, Karen Frei

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

We prospectively evaluated the clinical and biochemical responses to enzyme-replacement therapy (ERT) with macrophage-targeted glucocerebrosidase (Ceredase) infusions in 5 patients (age, 3.5-8.5 years) with type 3 Gaucher's disease. The patients were followed for up to 5 years. Enzyme dosage ranged from 120 to 480 U/kg of body weight/month. Systemic manifestations of the disease regressed in all patients. Neurological deficits remained stable in 3 patients and slightly improved in 1. One patient developed myoclonic encephalopathy. Cognitive deterioration occurred in 1 patient and electroencephalographic deterioration in 2. Sequential cerebrospinal fluid (CSF) samples were obtained during the first 3 years of treatment in 3 patients and were analyzed for biochemical markers of disease burden. Glucocerebroside and psychosine levels were not elevated in these specimens, whereas chitotriosidase and quinolinic acid were elevated in 2 patients. Progressive decrease in the CSF levels of these latter macrophage markers during 3 years of treatment implies a decreased number of Gaucher cells in the cerebral perivascular space. Similar changes were not observed in the patient who had a poor neurological outcome. In conclusion, ERT reverses systemic manifestations of type 3 Gaucher's disease and appears to reduce the burden of Gaucher cells in the brain-CSF compartment in some patients.

Original languageEnglish (US)
Pages (from-to)613-621
Number of pages9
JournalAnnals of Neurology
Volume42
Issue number4
DOIs
StatePublished - Oct 1997
Externally publishedYes

Fingerprint

Glucosylceramidase
Gaucher Disease
Macrophages
Prospective Studies
Enzyme Replacement Therapy
Cerebrospinal Fluid
Therapeutics
Psychosine
Myoclonic Epilepsy
Glucosylceramides
Quinolinic Acid
Cell Count
Biomarkers
Body Weight

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Schiffmann, R., Heyes, M. P., Aerts, J. M., Dambrosia, J. M., Patterson, M. C., DeGraba, T., ... Frei, K. (1997). Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Annals of Neurology, 42(4), 613-621. https://doi.org/10.1002/ana.410420412

Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. / Schiffmann, Raphael; Heyes, Melvyn P.; Aerts, J. M.; Dambrosia, James M.; Patterson, Marc C.; DeGraba, Thomas; Parker, Colette C.; Zirzow, Gregory C.; Oliver, Katherine; Tedeschi, Gioacchino; Brady, Roscoe O.; Barton, Norman W.; Nagineni, Chandra; Kaneski, Christine R.; Murray, Gary J.; Higgins, Joseph J.; Tournay, Anne; Banerjee, Tapas K.; Kreps, Constance; Scott, Leland J C; McKee, Mary Ann; Crutchfield, Kevin; Frei, Karen.

In: Annals of Neurology, Vol. 42, No. 4, 10.1997, p. 613-621.

Research output: Contribution to journalArticle

Schiffmann, R, Heyes, MP, Aerts, JM, Dambrosia, JM, Patterson, MC, DeGraba, T, Parker, CC, Zirzow, GC, Oliver, K, Tedeschi, G, Brady, RO, Barton, NW, Nagineni, C, Kaneski, CR, Murray, GJ, Higgins, JJ, Tournay, A, Banerjee, TK, Kreps, C, Scott, LJC, McKee, MA, Crutchfield, K & Frei, K 1997, 'Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease', Annals of Neurology, vol. 42, no. 4, pp. 613-621. https://doi.org/10.1002/ana.410420412
Schiffmann, Raphael ; Heyes, Melvyn P. ; Aerts, J. M. ; Dambrosia, James M. ; Patterson, Marc C. ; DeGraba, Thomas ; Parker, Colette C. ; Zirzow, Gregory C. ; Oliver, Katherine ; Tedeschi, Gioacchino ; Brady, Roscoe O. ; Barton, Norman W. ; Nagineni, Chandra ; Kaneski, Christine R. ; Murray, Gary J. ; Higgins, Joseph J. ; Tournay, Anne ; Banerjee, Tapas K. ; Kreps, Constance ; Scott, Leland J C ; McKee, Mary Ann ; Crutchfield, Kevin ; Frei, Karen. / Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. In: Annals of Neurology. 1997 ; Vol. 42, No. 4. pp. 613-621.
@article{c7444f5b71de49c29fef4080e4404a76,
title = "Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease",
abstract = "We prospectively evaluated the clinical and biochemical responses to enzyme-replacement therapy (ERT) with macrophage-targeted glucocerebrosidase (Ceredase) infusions in 5 patients (age, 3.5-8.5 years) with type 3 Gaucher's disease. The patients were followed for up to 5 years. Enzyme dosage ranged from 120 to 480 U/kg of body weight/month. Systemic manifestations of the disease regressed in all patients. Neurological deficits remained stable in 3 patients and slightly improved in 1. One patient developed myoclonic encephalopathy. Cognitive deterioration occurred in 1 patient and electroencephalographic deterioration in 2. Sequential cerebrospinal fluid (CSF) samples were obtained during the first 3 years of treatment in 3 patients and were analyzed for biochemical markers of disease burden. Glucocerebroside and psychosine levels were not elevated in these specimens, whereas chitotriosidase and quinolinic acid were elevated in 2 patients. Progressive decrease in the CSF levels of these latter macrophage markers during 3 years of treatment implies a decreased number of Gaucher cells in the cerebral perivascular space. Similar changes were not observed in the patient who had a poor neurological outcome. In conclusion, ERT reverses systemic manifestations of type 3 Gaucher's disease and appears to reduce the burden of Gaucher cells in the brain-CSF compartment in some patients.",
author = "Raphael Schiffmann and Heyes, {Melvyn P.} and Aerts, {J. M.} and Dambrosia, {James M.} and Patterson, {Marc C.} and Thomas DeGraba and Parker, {Colette C.} and Zirzow, {Gregory C.} and Katherine Oliver and Gioacchino Tedeschi and Brady, {Roscoe O.} and Barton, {Norman W.} and Chandra Nagineni and Kaneski, {Christine R.} and Murray, {Gary J.} and Higgins, {Joseph J.} and Anne Tournay and Banerjee, {Tapas K.} and Constance Kreps and Scott, {Leland J C} and McKee, {Mary Ann} and Kevin Crutchfield and Karen Frei",
year = "1997",
month = "10",
doi = "10.1002/ana.410420412",
language = "English (US)",
volume = "42",
pages = "613--621",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease

AU - Schiffmann, Raphael

AU - Heyes, Melvyn P.

AU - Aerts, J. M.

AU - Dambrosia, James M.

AU - Patterson, Marc C.

AU - DeGraba, Thomas

AU - Parker, Colette C.

AU - Zirzow, Gregory C.

AU - Oliver, Katherine

AU - Tedeschi, Gioacchino

AU - Brady, Roscoe O.

AU - Barton, Norman W.

AU - Nagineni, Chandra

AU - Kaneski, Christine R.

AU - Murray, Gary J.

AU - Higgins, Joseph J.

AU - Tournay, Anne

AU - Banerjee, Tapas K.

AU - Kreps, Constance

AU - Scott, Leland J C

AU - McKee, Mary Ann

AU - Crutchfield, Kevin

AU - Frei, Karen

PY - 1997/10

Y1 - 1997/10

N2 - We prospectively evaluated the clinical and biochemical responses to enzyme-replacement therapy (ERT) with macrophage-targeted glucocerebrosidase (Ceredase) infusions in 5 patients (age, 3.5-8.5 years) with type 3 Gaucher's disease. The patients were followed for up to 5 years. Enzyme dosage ranged from 120 to 480 U/kg of body weight/month. Systemic manifestations of the disease regressed in all patients. Neurological deficits remained stable in 3 patients and slightly improved in 1. One patient developed myoclonic encephalopathy. Cognitive deterioration occurred in 1 patient and electroencephalographic deterioration in 2. Sequential cerebrospinal fluid (CSF) samples were obtained during the first 3 years of treatment in 3 patients and were analyzed for biochemical markers of disease burden. Glucocerebroside and psychosine levels were not elevated in these specimens, whereas chitotriosidase and quinolinic acid were elevated in 2 patients. Progressive decrease in the CSF levels of these latter macrophage markers during 3 years of treatment implies a decreased number of Gaucher cells in the cerebral perivascular space. Similar changes were not observed in the patient who had a poor neurological outcome. In conclusion, ERT reverses systemic manifestations of type 3 Gaucher's disease and appears to reduce the burden of Gaucher cells in the brain-CSF compartment in some patients.

AB - We prospectively evaluated the clinical and biochemical responses to enzyme-replacement therapy (ERT) with macrophage-targeted glucocerebrosidase (Ceredase) infusions in 5 patients (age, 3.5-8.5 years) with type 3 Gaucher's disease. The patients were followed for up to 5 years. Enzyme dosage ranged from 120 to 480 U/kg of body weight/month. Systemic manifestations of the disease regressed in all patients. Neurological deficits remained stable in 3 patients and slightly improved in 1. One patient developed myoclonic encephalopathy. Cognitive deterioration occurred in 1 patient and electroencephalographic deterioration in 2. Sequential cerebrospinal fluid (CSF) samples were obtained during the first 3 years of treatment in 3 patients and were analyzed for biochemical markers of disease burden. Glucocerebroside and psychosine levels were not elevated in these specimens, whereas chitotriosidase and quinolinic acid were elevated in 2 patients. Progressive decrease in the CSF levels of these latter macrophage markers during 3 years of treatment implies a decreased number of Gaucher cells in the cerebral perivascular space. Similar changes were not observed in the patient who had a poor neurological outcome. In conclusion, ERT reverses systemic manifestations of type 3 Gaucher's disease and appears to reduce the burden of Gaucher cells in the brain-CSF compartment in some patients.

UR - http://www.scopus.com/inward/record.url?scp=0030772366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030772366&partnerID=8YFLogxK

U2 - 10.1002/ana.410420412

DO - 10.1002/ana.410420412

M3 - Article

C2 - 9382473

AN - SCOPUS:0030772366

VL - 42

SP - 613

EP - 621

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -